Literature DB >> 19028421

No short-term benefits of antenatal corticosteroid treatment in severely preterm growth restricted fetuses: a case-control study.

Giel van Stralen1, Jetske van der Bos, Enrico Lopriore, Arjan B Te Pas, Kitty W M Bloemenkamp, Frans J Walther, Sicco Scherjon.   

Abstract

BACKGROUND: Antenatal corticosteroid administration to premature, growth restricted fetuses may not be beneficial and even have adverse effects on neonatal outcome. AIMS: To determine if preterm growth restricted fetuses benefit from antenatal corticosteroids. STUDY
DESIGN: Retrospective cohort study.
METHODS: All singleton pregnancies with growth restricted fetuses delivered at our department before 34 weeks' gestation or weighing less than 1500 g, between January 2001 and December 2005, were retrospectively reviewed. Neonatal outcome was compared between growth restricted fetuses (defined as abnormal flow patterns in umbilical and middle cerebral arteries) that received antenatal CST (CST group) and those who did not receive antenatal CST (no CST group). The administration of CST appeared to be quasi randomized.
RESULTS: A total of 88 pregnancies fulfilled the inclusion criteria (CST group, n=54; no CST group, n=34). The incidence of neonatal respiratory distress syndrome in the CST and no CST group was 42% (22/54) and 50% (17/34), respectively (p=0.44). Neonatal mortality in the CST and no CST group was 9% (5/54) and 12% (4/34), respectively (p=0.73). The prevalence of adverse neonatal outcome (neonatal mortality, major neonatal morbidity or severe cerebral lesions) in the CST and no CST group was 28% (15/54) versus 24% (8/34), (p=0.62).
CONCLUSIONS: Administration of CST to growth restricted preterm fetuses does not appear to be beneficial with respect to short term neonatal outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028421     DOI: 10.1016/j.earlhumdev.2008.10.010

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  5 in total

Review 1.  Antenatal corticosteroids in preterm small-for-gestational age infants: a systematic review and meta-analysis.

Authors:  Stephanie A Blankenship; Kristine E Brown; Laura E Simon; Molly J Stout; Methodius G Tuuli
Journal:  Am J Obstet Gynecol MFM       Date:  2020-08-17

2.  Sex differences in modulation of fetoplacental vascular resistance in growth-restricted mouse fetuses following betamethasone administration: comparisons with human fetuses.

Authors:  Lindsay S Cahill; Shiri Shinar; Clare L Whitehead; Sebastian R Hobson; Greg Stortz; Viji Ayyathurai; Anjana Ravi Chandran; Anum Rahman; John C Kingdom; Ahmet Baschat; Kellie E Murphy; Lena Serghides; Christopher K Macgowan; John G Sled
Journal:  Am J Obstet Gynecol MFM       Date:  2020-10-06

3.  Judicious use of antenatal glucocorticoids: putting the risks into the balance.

Authors:  J Verhaeghe
Journal:  Facts Views Vis Obgyn       Date:  2011

Review 4.  Antenatal Corticosteroids for Reducing Adverse Maternal and Child Outcomes in Special Populations of Women at Risk of Imminent Preterm Birth: A Systematic Review and Meta-Analysis.

Authors:  Rachel M Amiya; Linda B Mlunde; Erika Ota; Toshiyuki Swa; Olufemi T Oladapo; Rintaro Mori
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

5.  Antenatal dexamethasone effect on Doppler blood flow velocity in women at risk for preterm birth: prospective case series.

Authors:  Elsnosy Elwany; Shaaban Omar; Abbas Ahmed; Gaber Heba; Darwish Atef
Journal:  Afr Health Sci       Date:  2018-09       Impact factor: 0.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.